Sort:
Open Access Research Article Issue
Sequential treatment of infectious bone defects with three dimensional-printed body temperature-responsive shape memory scaffold coated with metal-polyphenol layers
Burns & Trauma 2026, 14(2)
Published: 14 November 2025
Abstract PDF (4.4 MB) Collect
Downloads:0
Background

Infectious bone defects are characterized by persistent bacterial invasion and an immune microenvironment imbalance, which significantly hinders bone regeneration. Recently, numerous bone repair materials have been developed to address the complex pathological microenvironment associated with infectious bone defects. However, dynamic changes in the defect size after infectious debridement pose a significant challenge for achieving effective bone integration of artificial bone grafts. Therefore, there is a need to develop an integrated scaffold with antibacterial, immunomodulatory, and osteogenic properties to achieve filling of irregular bone defects.

Methods

Using low-temperature printing combined with the freeze-drying technology, a shape-memory scaffold with a biomimetic porous structure of cancellous bones was fabricated by compositing left-handed poly(L-lactic acid)-trimethylene carbonate (PLLA-TMC) with citric acid-modified hydroxyapatite (CHA). The scaffold (PT/CHA) was further coated with a metal-polyphenol network tannic acid-magnesium (TA-Mg) on its surface through the “mussel” effect, enabling the sequential treatment of infectious bone defects.

Results

The scaffold can adaptively integrate with defect interfaces at the physiological temperature (37℃), achieving superior bone integration performance. The incorporation of citric-acid-modified hydroxyapatite effectively optimizes the polymer-inorganic phase printing ink system, significantly enhancing the mechanical strength and mineralization capacity of the scaffold. Meanwhile, the external tannic-acid-magnesium metal-polyphenol coating (TA-Mg) demonstrates excellent pathogen clearance properties both in vitro and in vivo. It also influences macrophage polarization to regulate the immune microenvironment, ultimately promoting bone regeneration in infectious bone defects.

Conclusions

The PT/CHA@TA-Mg scaffold achieves bone integration through adaptive filling and enables the multi-stage treatment of infectious bone defects via antibacterial, immune-regulatory, and osteogenic differentiation.

Open Access Full Length Article Issue
Fibrous scaffolds loaded with BMSC-derived apoptotic vesicles promote wound healing by inducing macrophage polarization
Genes & Diseases 2025, 12(2): 101388
Published: 09 August 2024
Abstract PDF (5 MB) Collect
Downloads:27

Macrophages play a key role in wound healing. Dysfunction of their M0 polarization to M2 leads to disorders of the wound immune microenvironment and chronic inflammation, which affects wound healing. Regulating the polarization of M0 macrophages to M2 macrophages is an effective strategy for treating wound healing. Mesenchymal stem cells (MSCs) deliver endogenous regulatory factors via paracrine extracellular vesicles, which may play a key role in wound healing, and previous studies have shown that apoptotic bodies (ABs) are closely associated with inflammation regression and macrophage polarization. However, the specific regulatory mechanisms involved in ABs remain unknown. In the present study, we designed an MSC-AB (MSC-derived AB)-loaded polycaprolactone (PCL) scaffold, evaluated the macrophage phenotype and skin wound inflammation in vivo and in vitro, and explored the ability of MSC-AB-loaded PCL scaffolds to promote wound healing. Our data suggest that the PCL scaffold regulates the expression of the CCL-1 gene by targeting the delivery of mmu-miR-21a-5p by local sustained-release MSC-ABs, and drives M0 macrophages to program M2 macrophages to regulate inflammation and angiogenesis, thereby synergistically promoting wound healing. This study provides a promising therapeutic strategy and experimental basis for treating various diseases associated with imbalances in proinflammatory and anti-inflammatory immune responses.

Open Access Full Length Article Issue
The miR-21-5p enriched in the apoptotic bodies of M2 macrophage-derived extracellular vesicles alleviates osteoarthritis by changing macrophage phenotype
Genes & Diseases 2023, 10(3): 1114-1129
Published: 05 October 2022
Abstract PDF (6.2 MB) Collect
Downloads:9

Macrophages (Mφs) play a crucial role in the pathological progression of osteoarthritis (OA) by regulating inflammation and tissue repair. Decreasing pro-inflammatory M1-Mφs and increasing anti-inflammatory M2-Mφs can alleviate OA-related inflammation and promote cartilage repair. Apoptosis is a natural process associated with tissue repair. A large number of apoptotic bodies (ABs), a type of extracellular vesicle, are produced during apoptosis, and this is associated with a reduction in inflammation. However, the functions of apoptotic bodies remain largely unknown. In this study, we investigated the role of M2-Mφs-derived apoptotic bodies (M2-ABs) in regulating the M1/M2 balance of macrophages in a mouse model of OA. Our data show that M2-ABs can be targeted for uptake by M1-Mφs, and this reprograms M1-to-M2 phenotypes within 24 h. The M2-ABs significantly ameliorated the severity of OA, alleviated the M1-mediated pro-inflammatory environment, and inhibited chondrocyte apoptosis in mice. RNA-seq revealed that M2-ABs were enriched with miR-21–5p, a microRNA that is negatively correlated with articular cartilage degeneration. Inhibiting the function of miR-21–5p in M1-Mφs significantly reduced M2-ABs-guided M1-to-M2 reprogramming following in vitro cell transfection. Together, these results suggest that M2-derived apoptotic bodies can prevent articular cartilage damage and improve gait abnormalities in OA mice by reversing the inflammatory response caused by M1 macrophages. The mechanism underlying these findings may be related to miR-21-5p-regulated inhibition of inflammatory factors. The application of M2-ABs may represent a novel cell therapy, and could provide a valuable strategy for the treatment of OA and/or chronic inflammation.

Total 3